Dopamine injection
Products billed under this code include Dopamine, Dopamine In D5W.
Payment limit per 40 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Dopamine, Dopamine In D5W.
Payment limit per 40 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Dopamine | Hikma Pharmaceuticals USA Inc. | 00143-9252-25 | 125 | $102.875 |
| Dopamine | Hikma Pharmaceuticals USA Inc. | 00143-9254-25 | 250 | $205.75 |
| Dopamine | Henry Schein Inc. | 00404-9981-10 | 10 | $8.23 |
| Dopamine | Henry Schein Inc. | 00404-9982-05 | 5 | $4.115 |
| Dopamine | Pfizer Inc | 00409-5820-01 | 125 | $102.875 |
| Dopamine | Pfizer Inc | 00409-7809-22 | 120 | $98.76 |
| Dopamine | Pfizer Inc | 00409-7809-24 | 240 | $197.52 |
| Dopamine | Pfizer Inc | 00409-7810-22 | 240 | $197.52 |
| Dopamine | Pfizer Inc | 00409-9104-20 | 250 | $205.75 |
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1220-01 | 10 | $8.23 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1220-03 | 250 | $205.75 |
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1291-01 | 5 | $4.115 |
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1291-03 | 125 | $102.875 |
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1489-01 | 5 | $4.115 |
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1489-03 | 125 | $102.875 |
| Dopamine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1490-01 | 10 | $8.23 |
| Dopamine In D5W | Baxter Healthcare Corporation | 00338-1005-02 | 90 | $74.07 |
| Dopamine In D5W | Baxter Healthcare Corporation | 00338-1005-03 | 120 | $98.76 |
| Dopamine In D5W | Baxter Healthcare Corporation | 00338-1007-02 | 180 | $148.14 |
| Dopamine In D5W | Baxter Healthcare Corporation | 00338-1007-03 | 240 | $197.52 |
| Dopamine In D5W | Baxter Healthcare Corporation | 00338-1009-02 | 360 | $296.28 |
| Dopamine in D5W | Pfizer Inc | 00409-0042-12 | 120 | $98.76 |
| Dopamine in D5W | Pfizer Inc | 00409-1858-12 | 240 | $197.52 |
| Dopamine in D5W | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1316-01 | 10 | $8.23 |
| Dopamine in D5W | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1316-03 | 120 | $98.76 |
| Dopamine in D5W | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1458-01 | 20 | $16.46 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.823 | −$0.189 | 40 MG | Dopamine injection | v1, posted September 17, 2026 |
| 3Q26 | $1.012 | +$0.211 | 40 MG | Dopamine injection | v1, posted September 15, 2026 |
| 2Q26 | $0.801 | −$0.001 | 40 MG | Dopamine injection | v1, posted September 15, 2026 |
| 1Q26 | $0.802 | −$0.031 | 40 MG | Dopamine injection | v1, posted September 15, 2026 |
| 4Q25 | $0.833 | +$0.177 | 40 MG | Dopamine injection | v1, posted September 8, 2026 |
| 3Q25 | $0.656 | −$0.053 | 40 MG | Dopamine injection | v1, posted March 10, 2026 |
| 2Q25 | $0.709 | −$0.064 | 40 MG | Dopamine injection | v1, posted March 10, 2026 |
| 1Q25 | $0.773 | +$0.052 | 40 MG | Dopamine injection | v1, posted December 19, 2025 |
| 4Q24 | $0.721 | −$0.065 | 40 MG | Dopamine injection | v1, posted June 11, 2025 |
| 3Q24 | $0.786 | −$0.029 | 40 MG | Dopamine injection | v1, posted June 11, 2025 |
| 2Q24 | $0.815 | +$0.043 | 40 MG | Dopamine injection | v1, posted March 11, 2025 |
| 1Q24 | $0.772 | +$0.142 | 40 MG | Dopamine injection | v1, posted December 19, 2024 |
| 4Q23 | $0.63 | −$0.069 | 40 MG | Dopamine injection | v1, posted October 10, 2024 |
| 3Q23 | $0.699 | +$0.03 | 40 MG | Dopamine injection | v1, posted June 5, 2024 |
| 2Q23 | $0.669 | +$0.049 | 40 MG | Dopamine injection | v1, posted February 23, 2024 |
| 1Q23 | $0.62 | −$0.094 | 40 MG | Dopamine injection | v1, posted December 6, 2023 |
| 4Q22 | $0.714 | +$0.224 | 40 MG | Dopamine injection | v1, posted June 22, 2023 |
| 3Q22 | $0.49 | −$0.171 | 40 MG | Dopamine injection | v1, posted June 9, 2023 |
| 2Q22 | $0.661 | +$0.023 | 40 MG | Dopamine injection | v1, posted December 14, 2022 |
| 1Q22 | $0.638 | −$0.15 | 40 MG | Dopamine injection | v1, posted June 8, 2022 |
| 4Q21 | $0.788 | +$0.073 | 40 MG | Dopamine injection | v1, posted June 2, 2022 |
| 3Q21 | $0.715 | +$0.004 | 40 MG | Dopamine injection | v1, posted June 2, 2022 |
| 2Q21 | $0.711 | +$0.051 | 40 MG | Dopamine injection | v1, posted March 1, 2022 |
| 1Q21 | $0.66 | – | 40 MG | Dopamine injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.